Reduced mobilization of CD34+ stem cells in advanced human immunodeficiency virus type 1 disease

Journal of Infectious Diseases

Volumn 181, Issue 1, 2000, Pages 148-157

  Schooley, Robert T ^a,k   Mladenovic, Jeannette ^a   Sevin, Anne ^b   Chiu, Simon ^b   Miles, Steven A ^c   Pomerantz, Roger J ^e   Campbell, Thomas B ^a   Bell, Dawn ^g   Ambruso, Daniel ^a   Wong, Robbie ^d   Landay, Alan ⁱ   Coombs, Robert W ^j   Lawrence, Fox ^h   Kamoun, Malek ^f   Jacovini, Janice ^f  

^a UNIVERSITY OF COLORADO   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d AMGEN INC   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^h NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

ⁱ RUSH UNIVERSITY MEDICAL CENTER   (United States)

^j UNIVERSITY OF WASHINGTON   (United States)

^k UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ARTICLE; BONE MARROW CELL; CELL MOTILITY; CELL VIABILITY; CONTROLLED STUDY; ERYTHROID PRECURSOR CELL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; NONHUMAN; PRIORITY JOURNAL; STEM CELL; VIRUS REPLICATION;

ADULT; ANTIGENS, CD34; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DNA, VIRAL; FEMALE; FILGRASTIM; HEMATOPOIETIC STEM CELLS; HIV INFECTIONS; HIV-1; HUMANS; MALE; RNA, VIRAL; T-LYMPHOCYTE SUBSETS;

EID: 0033972199     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315168     Document Type: Article

References (65)

1. + cell counts 200 500 per cubic millimeter. N Engl J Med 1996;335:1081-90.
2. + cell counts of 200 per cubic millimeter or less. New Engl J Med 1997;337:725-33.
3. 3. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278:1295-300.
4. 4. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication competent HIV despite prolonged suppression of plasma viremia. Science 1997;278: 1291-5.
5. 5. D'Aquila RT, Johnson VA, Welles SL, et al. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann Intern Med 1995;122:401-8.
6. 6. Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance in ritonavir. Nat Med 1996;2:760-6.
7. 7. Carr A, Samaras K, Burton S, Freund J, Chisholm DJ, Cooper DA. A syndrome of peripheral lipodystrophy (LD), hyperlipidemia and insulin resistance due to HIV protease inhibitors (PIs) Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois. 1-5 February 1998, abstract 412.
8. 8. Mann M, Piazza-Hepp T, Koller E, Gibert C. Abnormal fat distribution in AIDS patients following protease inhibitor therapy: FDA Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois. 1-5 February 1998.
9. 9. Bridges SH, Sarver N. Gene therapy and immune restoration for HIV disease. Lancet 1995;345:427-32.
10. 10. Sarver N, Cantin EM, Chang PS, et al. Ribozymes as potential anti-HIV therapeutic agents. Science 1990;247:1222-5.
11. 11. Yu M, Ojwang J, Yamada O, et al. Intracellular immunization of human T-cells with a hairpin ribozyme against human immunodeficiency virus type 1. Gene Ther 1994;1:38-45.
12. 12. Malim MH, Freimuth WW, Liu J, et al. Functional dissection of the HIV-1 rev transactivator-derivation of transdominant repressor of Rev function. Cell 1989;58:205-14.
13. 13. Malim MH, Freimuth WW, Liu J, et. al. Stable expression of transdominant Rev protein in human T-cells inhibits human immunodeficiency virus replication. J Exp Med 1992;176:1197-20.
14. 14. Morasco WA, Haseltine WA, Chen SY, et al. Design, intracellular expression, and activity of a human immunodeficiency virus type 1 gp120 single-chain antibody. Proc Natl Acad Sci USA 1993;90:7889-93.
15. 15. Duan L, Bagasra O, Laughlin MA, et al. Potent inhibition of human immunodeficiency virus type 1 replication by an intracellular anti-Rev single-chain antibody. Proc Natl Acad Sci USA 1994;91:5075-9.
16. 16. Brady, HJ, Miles CG, Pennington DJ, Dzierzak EA. Specific ablation of human immunodeficiency virus Tat-expressing cells by conditionally toxic retroviruses. Proc Natl Acad Sci USA 1994;91:365-9.
17. + cells harboring a human immunodeficiency virus-inducible suicide gene prevents viral spread in an infected cell population. Proc Natl Acad Sci USA 1992;89:182-6.
18. 18. Curiel TJ, Cook DR, Wang Y, et al. Long-term inhibition of clinical and laboratory human immunodeficiency virus strains in human T-cell lines containing an human immunodeficiency virus (HIV)-regulated diphtheria toxin A chain gene. Hum Gene Ther 1993;4:741-7.
19. 19. Bonyhadi ML, Moss K, Voytovich A, et al. RevM10-expressing T cells derived in vivo from transduced human hematopoietic stem-progenitor cells inhibit human immunodeficiency virus replication. J Virol 1997;71: 4707-16.
20. + cells from HIV-1 infected donors using retroviral vectors containing anti-HIV 1 genes. Blood 1997;89:2259-67.
21. + hematopoietic progenitor cells with an antitat gene protects T-cell and macrophage progeny from AIDS virus infection. J Virol 1997;71:2740-6.
22. + hematopoietic progenitor cells by a retroviral vector expressing an RRE decoy inhibits human immunodeficiency virus type 1 replication in myelomonocytic cells produced in long-term culture. J Virol 1996;70:4352-60.
23. 23. Mielcarek M, Torok-Storb B. Phenotype and engraftment potential of cytokine-mobilized peripheral blood mononuclear cells. Curr Opin Hematol 1997;4:176-82.
24. 24. Bensinger WI, Clift RA, Anasetti C, et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony stimulating factor. Stem Cells 1996;14:90-105.
25. + cells in healthy people. Transfus Med 1997;7:19-24.
26. + cells in normal donors treated with filgrastim. Transfusion 1997; 37:507-12.
27. +/Thyldim progenitor cells during recombinant human granulocyte-colony-stimulating factor administration in normal donors. Transfusion 1997;37: 406-10.
28. + progenitor cells and lymphoid subsets in normal donors for allogeneic transplantation. Br J Haematol 1996;93: 940-2.
29. 29. Anderlini P, Lauppe J, Przepiorka D, et al. Peripheral blood stem cell apheresis in normal donors: feasibility and yield of second collections. Br J Haematol 1997;96:415-7.
30. 30. Elliott C, Samson DM, Armitage S, et al. When to harvest peripheral-blood stem cells after mobilization therapy: prediction of CD34-positive cell yield by preceding day CD34-positive concentration in peripheral blood. J Clin Oncol 1996;14:970-3.
31. 31. Grigg AP, Roberts AW, Raunow H, et al. Optimizing dose and scheduling of filgrastim (granulocyte-colony stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. Blood 1995;86:4437-45.
32. 32. Tanaka R, Matsudaira T, Aizawa J, et al., Characterization of peripheral blood progenitor cells (PBPC) mobilized by filgrastim (rHuG-CSF) in normal volunteers: dose-effect relationship for filgrastim with the character of mobilized PBPC. Br J Haematol 1996;92:795-803.
33. + peripheral blood cells from healthy adults mobilized by recombinant human granulocyte-colony stimulating factor. Blood 1994; 84:2795-801.
34. 34. Miles SA, Mitsuyasu RT, Lee K, et al., Recombinant human granulocyte-colony stimulating factor increases burst forming-erythron and red blood cell production in patients with severe human immunodeficiency virus infection. Blood 1990;75:2137-42.
35. 35. Miles SA, Mitsuyasu RT, Moreno, et al. Combined therapy with recombinant granulocyte colony-stimulating factor and erythropoietin decreases hematologic toxicity from zidovudine. Blood 1991;77:2109-17.
36. 36. Nielsen SD, Dam-Larsen S, Nielsen C, et al. Recombinant human granulocyte-colony stimulating factor increases circulating CD34-postive cells in patients with AIDS. Ann Hematol 1997;74:215-20.
37. + progenitor cells by granulocyte colony-stimulating factor in human immunodeficiency virus type 1-infected adults. Blood 1996;88:3329-35.
38. + peripheral blood stem cells from asymptomatic human immunodeficiency virus type-1-infected individuals mobilized with granulocyte colony-stimulating factor. Blood 1997;89: 4299-306.
39. + cells and CD34 cells makes G-CSF a candidate for use in gene therapy or to support antiretroviral therapy. J Infect Dis 1998;177:1733-6.
40. 40. Coombs RW, Peterson G. Estimates of HIV-1 proviral DNA copy number using a novel quantitative competitive PCR enzyme immunoassay (QC-PCR-EIA). Keystone Symposium on HIV-1 Pathogenesis and Treatment, Keystone, CO), 1998.
41. 41. Hollnger FB, Bremer JW, Myers LE, Gold JWM, LcQuay L. The NIH/ NIAID/DAIDS/ACTG Virology Laboratories: Standardization of sensitive human immunodeficiency virus coculture procedures and establishment of a multicenter quality assurance program for the AIDS Clinical Trials Group. J Clin Microbiol 1992;30:1787-95.
42. + cells using the Amgen cell selection device results in high levels of purity and recovery. J Hematother 1997;6:5-11.
43. + cells in peripheral and cord blood by flow cytometry. Exp Hematol 1994;22:1003-10.
44. 44. Campbell TB, Sevin A, Coombs RW, et al. Changes in human immunodeficiency virus type 1 virus load during mobilization and harvesting of hematopoietic progenitor cells. Blood 2000;95:48-55.
45. + and CFU-GM progenitors are significantly decreased in SIV smm9 infected rhesus macaques with minimal evidence of direct viral infection by polymerase chain reaction. Am J Hematol 1993;43:274-8.
46. 46. Re MC, Zauli G, Furlini G, et al. The impaired number of circulating granulocyte/macrophage progenitors (CFU-GM) in human immunodeficiency virus-type 1 infected subjects correlates with an active HIV-1 replication. Arch Virol 1993;129:53-64.
47. 47. Nielsen SD, Ersboll AK, Mathiesen L, Nielsen JO, Hansen JES. Highly active antiretroviral therapy normalizes the function of progenitor cells in human immunodeficiency virus-infected patients. J Infect Dis 1998;178: 1299-1305.
48. 48. Folks TM, Kessler SW, Orenstein JM, Justement JS, Jaffe ES, Fauci AS. Infection and replication of HIV-1 in purified progenitor cells of normal human bone marrow. Science 1988;242:919-22.
49. + hematopoietic progenitor cells are not a major reservoir of the human immunodeficiency virus. Blood 1990;76:1281-6.
50. 50. Davis BR, Schwartz DH, Marx JC, et al. Absent or rare human immunodeficiency virus infection of bone marrow stem/progenitor cells in vivo. J Virol 1991;65:1985-90.
51. + bone marrow cells are infected with HIV in a subset of seropositive individuals. J Immunol 1992;149:689-97.
52. + progenitor cells from asymptomatic patients are not a major reservoir for human immunodeficiency virus-1. Blood 1995;86:1749-56.
53. + progenitor cells are not infected by HIV-1 in vivo but show impaired clonogenesis. Br J Haematol 1993;85:20-4.
54. +) cells purified from the bone marrow of AIDS patients are committed to apoptotic cell death in culture. AIDS 1993;7:1049-55.
55. 55. Marandin A, Katz A, Oksenhendler E, et al. Loss of primitive hematopoietic progenitors in patients with human immunodeficiency virus infection. Blood 1996;88:4568-78.
56. + hematopoietic progenitor cells by human immunodeficiency virus 1 or gp120 mediated by endogenous transforming growth factor beta 1. J Exp Med 1996;183:99-108.
57. +) hematopoietic progenitor cells. Arch Virol 1992;122: 271-80.
58. 58. Rameshwar P, Denny TN, Gascon P. Enhanced HIV-1 activity in bone marrow can lead to myelopoietic suppression partially contributed by gag p24. J Immunol 1996;157:4244-50.
59. +) cells in AIDS patients. J Infect Dis 1992;166:710-6.
60. 60. Steinberg HN, Crumpacker CS, Chatis PA. In vitro suppression of normal human bone marrow progenitor cells by human immunodeficiency virus. J Virol 1991;65:1765-9.
61. +) hematopoietic progenitors. J Acquir Immune Defic Syndr 1991;4:1251-3.
62. 62. Bahner I, Kearns K, Coutinho S, Leonard EH, Kohn DB. Infection of human marrow stroma by human immunodeficiency virus-1 (HIV-1) is both required and sufficient for HIV-1-induced hematopoietic suppression in vitro: demonstration by gene modification of primary human stroma. Blood 1997;90:1787-98.
63. + cells to human immunodeficiency virus type 1 does not influence their expansion and proliferation of hematopoietic progenitors in vitro. Blood 1996;88:130-7.
64. 64. Marandin A, Canque B, Coulombel L, Gluckman JC, Vainchenker W, Louache F. In vitro infection of bone marrow-adherent cells by human immunodeficiency virus type 1 (HIV-1) does not alter their ability to support hematopoiesis. Virology 1995;213:245-8.
65. + T cell homeostasis and function in advanced HIV disease. Science 1997;277:112-6.